L. G. Gisclon

684 total citations
16 papers, 579 citations indexed

About

L. G. Gisclon is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, L. G. Gisclon has authored 16 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Oncology. Recurrent topics in L. G. Gisclon's work include Drug Transport and Resistance Mechanisms (6 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Antibiotics Pharmacokinetics and Efficacy (6 papers). L. G. Gisclon is often cited by papers focused on Drug Transport and Resistance Mechanisms (6 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Antibiotics Pharmacokinetics and Efficacy (6 papers). L. G. Gisclon collaborates with scholars based in United States, Poland and Israel. L. G. Gisclon's co-authors include Dennis R. Doose, R. K. Nayak, Christopher R. Curtin, Sally A. Walker, Jaya Natarajan, Kathleen M. Giacomini, R. Rex Williams, KM Giacomini, Wing K. Cheung and Andrew Chow and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Pharmaceutical Research and Epilepsia.

In The Last Decade

L. G. Gisclon

13 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. G. Gisclon United States 10 228 218 158 136 131 16 579
EJ Begg New Zealand 13 283 1.2× 214 1.0× 76 0.5× 158 1.2× 178 1.4× 19 851
Christopher R. Curtin United States 13 232 1.0× 190 0.9× 185 1.2× 96 0.7× 168 1.3× 24 802
R. K. Nayak United States 16 280 1.2× 406 1.9× 435 2.8× 123 0.9× 133 1.0× 26 986
Irwin Ho United States 12 226 1.0× 89 0.4× 90 0.6× 68 0.5× 91 0.7× 18 504
K A DeSante United States 15 268 1.2× 131 0.6× 173 1.1× 75 0.6× 87 0.7× 39 730
D. Beermann Germany 13 293 1.3× 83 0.4× 37 0.2× 105 0.8× 102 0.8× 22 526
R. Wayne Frost United States 12 323 1.4× 118 0.5× 30 0.2× 105 0.8× 123 0.9× 16 589
T. B. Tjandramaga Belgium 15 373 1.6× 179 0.8× 49 0.3× 106 0.8× 66 0.5× 41 818
William H. Pitlick United States 12 89 0.4× 347 1.6× 247 1.6× 48 0.4× 99 0.8× 20 777
Richard J. Fruncillo United States 12 166 0.7× 122 0.6× 83 0.5× 169 1.2× 50 0.4× 29 719

Countries citing papers authored by L. G. Gisclon

Since Specialization
Citations

This map shows the geographic impact of L. G. Gisclon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. G. Gisclon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. G. Gisclon more than expected).

Fields of papers citing papers by L. G. Gisclon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. G. Gisclon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. G. Gisclon. The network helps show where L. G. Gisclon may publish in the future.

Co-authorship network of co-authors of L. G. Gisclon

This figure shows the co-authorship network connecting the top 25 collaborators of L. G. Gisclon. A scholar is included among the top collaborators of L. G. Gisclon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. G. Gisclon. L. G. Gisclon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Gisclon, L. G., Angela Bowen, Terry O’Reilly, et al.. (2011). Bioequivalence of a Newly Developed 17β-Estradiol Tablet versus an Identical Reference Formulation. Arzneimittelforschung. 50(10). 910–914.
2.
Sachdeo, Rǎjesh C., René H. Levy, Anthony J. Streeter, et al.. (2002). Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic Patients. Epilepsia. 43(7). 691–696. 50 indexed citations
3.
Gisclon, L. G., et al.. (2000). Lack of Effect of a High‐Fat Meal on the Bioavailability of 17β‐Estradiol/Norgestimate in Healthy Postmenopausal Women. The Journal of Clinical Pharmacology. 40(7). 762–769. 1 indexed citations
4.
Gisclon, L. G., et al.. (1999). A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. Journal of Pharmaceutical and Biomedical Analysis. 19(3-4). 363–371. 39 indexed citations
5.
Gisclon, L. G., Christopher R. Curtin, Cynthia L. Fowler, et al.. (1997). Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin. The Journal of Clinical Pharmacology. 37(8). 744–750. 22 indexed citations
6.
Chien, Shuchean, Mark Rogge, L. G. Gisclon, et al.. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy. 41(10). 2256–2260. 189 indexed citations
7.
Gisclon, L. G., et al.. (1996). The pharmacokinetics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis. 36. 3. 9 indexed citations
8.
Doose, Dennis R., Sally A. Walker, L. G. Gisclon, & R. K. Nayak. (1996). Single‐Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, A Novel Antiepileptic Drug. The Journal of Clinical Pharmacology. 36(10). 884–891. 106 indexed citations
9.
Gisclon, L. G., Keith Wesnes, Christopher R. Curtin, et al.. (1996). Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men*. Clinical Pharmacology & Therapeutics. 59(6). 675–685. 6 indexed citations
10.
Gisclon, L. G., Rebecca A. Boyd, Roger Williams, & Kathleen M. Giacomini. (1989). The effect of probenecid on the renal elimination of cimetidine. Clinical Pharmacology & Therapeutics. 45(4). 444–452. 45 indexed citations
11.
Gisclon, L. G. & Kathleen M. Giacomini. (1988). Inhibition of cimetidine transport by creatinine in luminal membrane vesicles prepared from rabbit kidney.. Drug Metabolism and Disposition. 16(2). 331–332. 19 indexed citations
12.
Giacomini, Kathleen M., Poe‐Hirr Hsyu, & L. G. Gisclon. (1988). Renal transport of drugs: an overview of methodology with application to cimetidine.. Pharmaceutical Research. 5(8). 465–471. 7 indexed citations
13.
Hsyu, P., L. G. Gisclon, Andrew Hui, & KM Giacomini. (1988). Interactions of organic anions with the organic cation transporter in renal BBMV. American Journal of Physiology-Renal Physiology. 254(1). F56–F61. 39 indexed citations
14.
Gisclon, L. G., et al.. (1987). Cimetidine transport in isolated luminal membrane vesicles from rabbit kidney. American Journal of Physiology-Renal Physiology. 253(1). F141–F150. 32 indexed citations
15.
Gisclon, L. G., et al.. (1979). Pharmacokinetics of orally administered dyphylline. American Journal of Health-System Pharmacy. 36(9). 1179–1184. 14 indexed citations
16.
Gisclon, L. G., et al.. (1979). Saliva, urine and plasma analysis of dyphylline via HPLC.. PubMed. 23(3). 523–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026